Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) adopted positive opinions, recommending marketing authorisations, ...
Novo Nordisk's new long-acting insulin, Tresiba, has been shown to be effective and safe for long-term use in children and young adults with type 1 diabetes, according to new data from a late-stage ...
The Tresiba label was updated to reflect safety outcomes from the DEVOTE trial. Novo Nordisk announced that the Food and Drug Administration (FDA) has approved an update to the prescribing information ...
Novo Nordisk, a world leader in diabetes care, today announced that the U.S. Food and Drug Administration (FDA) approved the new drug application for Tresiba ® (insulin degludec injection), a ...
Novo Nordisk presented the latest results for its diabetes injectable Tresiba last weekend. These demonstrated significantly better control of blood sugar levels than Sanofi’s Toujeo, with additional ...
Bagsværd, Denmark, 29 January 2016 - Novo Nordisk today announced the headline results from SWITCH 2, the first of two 2x32-weeks randomised, double-blind, cross-over, treat-to-target trials, ...
PLAINSBORO, N.J., Jan. 26, 2016 /PRNewswire/ -- Novo Nordisk, a world leader in diabetes care, today announced the availability of its newest insulin, Tresiba® (insulin degludec injection), a ...
Novo Nordisk ( NVO) recently presented new data on its type II diabetes drug, Tresiba (degludec), from a one-year extension study, BEGIN ONCE LONG. Data from the study was presented at the 73 rd ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback